Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank
Ms. Rhoads added, "The remaining proceeds from the offering will add to our financial resources as we continue developing the Company's product portfolio. Our current cash position gives us sufficient capital to continue the commercialization of SUMAVEL® DosePro®, advance through potential commercialization of Zohydro™ ER, and move forward with our earlier stage candidate, Relday™. Together, these three programs represent a potentially significant growth opportunity for
For additional information, please visit www.zogenix.com.
Forward Looking Statements
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and
SUMAVEL ®, DosePro ®, Relday™ and Zohydro™ ER are trademarks of
Zack Kubow| The Ruth Group646.536.7020 | email@example.com MEDIA: Victoria Aguiar| The Ruth Group646.536.7013 | firstname.lastname@example.org